Lilly: the full-year drug-sales test
Lilly’s October outlook puts 2026 revenue at $91B–$92B, led by Mounjaro and Zepbound. The midpoint tests commercialization separately from trial outcomes.
Eli Lilly and Company / LLYPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
Lilly Q3 2026 results and full-year outlookPublished 2026-10-29
Potential outcome market
Will Lilly full-year 2026 revenue exceed $91.5 billion?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.